Global Tuberculosis Report 2022. Accessed August 30, 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.
Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transpl. 2005;36:757–769. https://doi.org/10.1038/sj.bmt.1705140.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: a global perspective. Biol Blood Marrow Transpl. 2009;15:1143–1238. https://doi.org/10.1016/j.bbmt.2009.06.019.
Cheng MP, Kusztos AE, Bold TD, Ho VT, Glotzbecker BE, Hsieh C, et al. Risk of latent tuberculosis reactivation after hematopoietic cell transplantation. Clin Infect Dis. 2019;69:869–872. https://doi.org/10.1093/cid/ciz048.
Kapoor J, Mirgh SP, Khushoo V, Mehta P, Ahmed R, Bansal N, et al. Study of clinical characteristics, risk factors and outcomes for tuberculosis post-allogeneic stem cell transplant: never count it out. Ther Adv Infect Dis. 2021;8:204993612110086 https://doi.org/10.1177/20499361211008674.
Zeng QZ, Zhang YY, Wu YJ, Zhang ZY, Zhang JN, Fu HX, et al. Frequency, risk factors, and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2020;26:1203–9. https://doi.org/10.1016/j.bbmt.2020.02.018.
de Oliveira Rodrigues M, de Almeida Testa LH, dos Santos ACF, Zanetti LP, da Silva Ruiz L, de Souza MP, et al. Latent and active tuberculosis infection in allogeneic hematopoietic stem cell transplant recipients: a prospective cohort study. Bone Marrow Transpl. 2021;56:2241–7. https://doi.org/10.1038/s41409-021-01329-3.
Lee HJ, Lee DG, Choi SM, Park SH, Cho SY, Choi JK, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS ONE. 2017;12:e0173250. https://doi.org/10.1371/journal.pone.0173250.
Fan WC, Liu CJ, Hong YC, Feng JY, Su WJ, Chien SH, et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. Int J Tuberc Lung Dis. 2015;19:58–64. https://doi.org/10.5588/ijtld.14.0301.
Liu YC, Wu CJ, Ko PS, Chien SH, Fan NW, Wang HY, et al. Mycobacterial infections in adult recipients of allogeneic hematopoietic stem cell transplantation: a cohort study in a high-endemic area. J Microbiol Immunol Infect. 2020;53:274–82. https://doi.org/10.1016/j.jmii.2018.07.001.
Bergeron A, Mikulska M, Greef JD, Bondeelle L, Franquet T, Herrmann JL, et al. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia. Lancet Infect Dis. 2022;0. https://doi.org/10.1016/S1473-3099(22)00227-4.
de Léotoing L, Barbier F, Dinh A, Breilh D, Chaize G, Vainchtock A, et al. French hospital discharge database (PMSI) and bacterial resistance: Is coding adapted to hospital epidemiology? Méd Mal Infect. 2018;48:465–73. https://doi.org/10.1016/j.medmal.2018.03.007.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. Am J Med. 1980;69:204–17. https://doi.org/10.1016/0002-9343(80)90380-0.
Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2003;9:215–33. https://doi.org/10.1053/bbmt.2003.50026.
Guidelines on the management of latent tuberculosis infection. Accessed June 22, 2023. https://www.who.int/publications-detail-redirect/9789241548908.
Yang A, Shi J, Luo Y, Ye Y, Tan Y, Huang H, et al. Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis. Sci Rep. 2019;9:20402. https://doi.org/10.1038/s41598-019-56013-w.
Peer V, Schwartz N, Green MS Gender differences in tuberculosis incidence rates—A pooled analysis of data from seven high-income countries by age group and time period. Front Public Health. 2023;10. https://doi.org/10.3389/fpubh.2022.997025.
Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13:1–13. https://doi.org/10.1038/s41408-023-00853-3.
Agrawal N, Aggarwal M, Kapoor J, Ahmed R, Shrestha A, Kaushik M, et al. Incidence and clinical profile of tuberculosis after allogeneic stem cell transplantation. Transpl Infect Dis. 2018;20:e12794. https://doi.org/10.1111/tid.12794.
Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33:844–62. https://doi.org/10.1038/s41375-019-0388-x.
Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J. 2012;40:990–1013. https://doi.org/10.1183/09031936.00000712.
de la Cámara R, Martino R, Granados E, Rodríguez-Salvanés FJ, Rovira M, Cabrera R, et al. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Bone Marrow Transpl. 2000;26:291–8. https://doi.org/10.1038/sj.bmt.1702506.
Gras J, De Castro N, Montlahuc C, Champion L, Scemla A, Matignon M, et al. Clinical characteristics, risk factors, and outcome of tuberculosis in kidney transplant recipients: A multicentric case-control study in a low-endemic area. Transpl Infect Dis. 2018;20:e12943. https://doi.org/10.1111/tid.12943.
Sartori NS, Picon P, Papke A, Neyeloff JL, da Silva Chakr RM. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment. PLoS ONE. 2019;14:e0224963 https://doi.org/10.1371/journal.pone.0224963.
Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to a significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–7. https://doi.org/10.1002/art.11137.
Gupta RK, Rice B, Brown AE, Thomas HL, Zenner D, Anderson L, et al. Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV. 2015;2:e243–e251. https://doi.org/10.1016/S2352-3018(15)00063-6.
Winter JR, Stagg HR, Smith CJ, Brown AE, Lalor MK, Lipman M, et al. Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV. AIDS. 2017;31:2403–13. https://doi.org/10.1097/QAD.0000000000001635.
Karo B, Haas W, Kollan C, Gunsenheimer-Bartmeyer B, Hamouda O, et al. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis. 2014;14:148. https://doi.org/10.1186/1471-2334-14-148.
Turkova A, Chappell E, Judd A, Goodall RL, Welch SB, Foster C, et al. Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study. Lancet HIV. 2015;2:e530–e539. https://doi.org/10.1016/S2352-3018(15)00200-3.
Martin-Iguacel R, Llibre JM, Pedersen C, Obel N, Stærke NB, Åhsberg J, et al. Tuberculosis incidence and mortality in people living with human immunodeficiency virus: a Danish nationwide cohort study. Clin Microbiol Infect. 2022;28:570–9. https://doi.org/10.1016/j.cmi.2021.07.036.
Abgrall S, Del Giudice P, Melica G, Costagliola D. FHDH-ANRS CO4. HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. AIDS Lond Engl. 2010;24:763–71. https://doi.org/10.1097/QAD.0b013e3283366747.
Lannoy LHde, Cortez-Escalante JJ, Evangelista MdoSN, Romero GAS. Tuberculosis incidence and risk factors among patients living with HIV/AIDS in public health service institutions in Brasilia, Federal District. Rev Soc Bras Med Trop. 2008;41:549–55. https://doi.org/10.1590/S0037-86822008000600001.
Al-Anazi K, Al-Jasser A, Evans D. Infections caused by Mycobacterium tuberculosis in patients with hematological disorders and in recipients of hematopoietic stem cell transplant, a twelve-year retrospective study. Ann Clin Microbiol Antimicrob. 2007;6:16 https://doi.org/10.1186/1476-0711-6-16.
Kwon DE, Han SH, Han KD, La Y, Lee KH. Incidence rate of active tuberculosis in solid organ transplant recipients: data from a nationwide population cohort in a high-endemic country. Transpl Infect Dis. 2021;23:e13729. https://doi.org/10.1111/tid.13729.
Helleberg M, Cho D, Ekenberg C, Sørensen S, Rix M, Gustafsson F, et al. Tuberculosis among patients undergoing solid organ transplantation or dialysis in a low-endemic country, 2004–17. Tuberc Res Treat. 2020;2020:1–7. https://doi.org/10.1155/2020/7636975.
Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort. Clin Infect Dis. 2009;48:1657–65. https://doi.org/10.1086/599035.
Natori Y, Ferreira VH, Nellimarla S, Husain S, Rotstein C, Humar A, et al. Incidence, outcomes, and long-term immune response to tuberculosis in organ transplant recipients. Transplantation. 2019;103:210–5. https://doi.org/10.1097/TP.0000000000002340.
Liu J, Yan J, Wan Q, Ye Q, Huang Y. The risk factors for tuberculosis in liver or kidney transplant recipients. BMC Infect Dis. 2014;14:387. https://doi.org/10.1186/1471-2334-14-387.
Garces Ambrossi G, Jakubowski A, Feinstein MB, Weinstock DM. Active tuberculosis limited to foreign-born patients after allogeneic hematopoietic stem cell transplant. Bone Marrow Transpl. 2005;36:741–3. https://doi.org/10.1038/sj.bmt.1705129.
Litvoc MN, Leal FE, Ferreira DB, Ferreira Lopes MIB, Capuani L, Rocha VG, et al. High tuberculosis density incidence rate in matched unrelated allogeneic stem cell transplantation recipients in the State of São Paulo, Brazil. Mediterr J Hematol Infect Dis. 2023;15:e2023037 https://doi.org/10.4084/MJHID.2023.037.
Yoo JW, Jo KW, Kim SH, Lee SO, Kim JJ, Park SK, et al. Incidence, characteristics, and treatment outcomes of mycobacterial diseases in transplant recipients. Transpl Int. 2016;29:549–58. https://doi.org/10.1111/tri.12752.
Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Lee JW, et al. Current trends of infectious complications following hematopoietic stem cell transplantation in a single center. J Korean Med Sci. 2006;21:199–207. https://doi.org/10.3346/jkms.2006.21.2.199.
Yoo JH, Lee DG, Choi SM, Choi JH, Park YH, Kim YJ, et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transpl. 2004;34:497–504. https://doi.org/10.1038/sj.bmt.1704636.
Lee J, Lee MH, Kim WS, Kim K, Park SH, Lee SH, et al. Tuberculosis in hematopoietic stem cell transplant recipients in Korea. Int J Hematol. 2004;79:185–8. https://doi.org/10.1532/IJH97.A10219.
George B, Mathews V, Srivastava A, Chandy M. Infections among allogeneic bone marrow transplant recipients in India. Bone Marrow Transpl. 2004;33:311–5. https://doi.org/10.1038/sj.bmt.1704347.
Erdstein AA, Daas P, Bradstock KF, Robinson T, Hertzberg MS. Tuberculosis in allogeneic stem cell transplant recipients: still a problem in the 21st century. Transpl Infect Dis. 2004;6:142–6. https://doi.org/10.1111/j.1399-3062.2004.00068.x.
Moon SM, Lee SO, Choi SH, Kim YS, Woo JH, Yoon DH, et al. Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis. 2013;15:104–9. https://doi.org/10.1111/j.1399-3062.2012.00765.x.
Kumar R, Naithani R, Mishra P, Mahapatra M, Seth T, Dolai TK, et al. Allogeneic hematopoietic SCT performed in non-HEPA filter rooms: initial experience from a single center in India. Bone Marrow Transpl. 2009;43:115–9. https://doi.org/10.1038/bmt.2008.307.
Ullah K, Raza S, Ahmed P, atti TM, Ikram A, Chaudhry QU, et al. Pulmonary tuberculosis in allogeneic stem cell transplant recipients. JPMA J Pak Med Assoc. 2007;57:567–9.
Maeda T, Kusumi E, Kami M, Kawabata M, Le Pavoux A, Hara S, et al. Disseminated tuberculosis following reduced-intensity cord blood transplantation for adult patients with hematological diseases. Bone Marrow Transpl. 2005;35:91–97. https://doi.org/10.1038/sj.bmt.1704740.
Ahmed P, Anwar M, Khan B, Altaf C, Ullah K, Raza S, et al. Role of isoniazid prophylaxis for prevention of tuberculosis in haemopoietic stem cell transplant recipients. J Pak Med Assoc. 2005;55. https://pubmed.ncbi.nlm.nih.gov/16302471/.
Ku SC, Tang JL, Hsueh PR, Luh KT, Yu CJ, Yang PC, et al. Pulmonary tuberculosis in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;27:1293–7. https://doi.org/10.1038/sj.bmt.1703092.
Budak-Alpdogan T, Tangün Y, Kalayoglu-Besisik S, Ratip S, Akan H, Baslar Z, et al. The frequency of tuberculosis in adult allogeneic stem cell transplant recipients in Turkey. Biol Blood Marrow Transpl. 2000;6:370–4. https://doi.org/10.1016/S1083-8791(00)70013-9.
Aljurf M, Gyger M, Alrajhi A, Sahovic E, Chaudhri N, Musa M, et al. Mycobacterium tuberculosis infection in allogeneic bone marrow transplantation patients. Bone Marrow Transpl. 1999;24:551–4. https://doi.org/10.1038/sj.bmt.1701930.
Ip MSM, Yuen KY, Woo PCY, Luk WK, Tsang KW, Lam WK, et al. Risk factors for pulmonary tuberculosis in bone marrow transplant recipients. Am J Respir Crit Care Med. 1998;158:1173–7. https://doi.org/10.1164/ajrccm.158.4.9712072.
Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20-year retrospective review. Bone Marrow Transpl. 1997;19:467–70. https://doi.org/10.1038/sj.bmt.1700686.
Benito N, García-Vázquez E, Horcajada JP, González J, Oppenheimer F, Cofán F, et al. Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: a retrospective matched cohort study. Clin Microbiol Infect. 2015;21:651–8. https://doi.org/10.1016/j.cmi.2015.03.010.
Li T, Zhang B, Du X, Pei S, Jia Z, Zhao Y. Recurrent pulmonary tuberculosis in China, 2005 to 2021. JAMA Netw Open. 2024;7:e2427266 https://doi.org/10.1001/jamanetworkopen.2024.27266.
Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3–20. https://doi.org/10.1128/CMR.00034-13.
Mert D, Ozer M, Merdin A, İskender G, Uncu Ulu B, Kizil Çakar M, et al. Latent tuberculosis in adult hematopoietic stem cell transplantation recipients: clinical experience from a previously endemic population. Medicine. 2022;101:e31786 https://doi.org/10.1097/MD.0000000000031786.
Bourlon C, Camacho-Hernández R, Fierro-Angulo OM, Acosta-Medina AA, Bourlon MT, Niembro-Ortega MD, et al. Latent tuberculosis in hematopoietic stem cell transplantation: diagnostic and therapeutic strategies to prevent disease activation in an endemic population. Biol Blood Marrow Transpl. 2020;26:1350–4. https://doi.org/10.1016/j.bbmt.2020.03.013.
Lee YM, Lee SO, Choi SH, Kim YS, Woo JH, Kim DY, et al. A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. J Infect. 2014;69:165–73. https://doi.org/10.1016/j.jinf.2014.02.019.
Castro-Lima VAC, Santos APT, Musqueira PT, Maluf NZ, Ramos JF, Mariano L, et al. Prevalence of latent Mycobacterium tuberculosis infection in hematopoietic stem cell transplantation comparing tuberculin skin test and interferon-gamma release assay. Eur J Clin Microbiol Infect Dis. 2023;42:899–902. https://doi.org/10.1007/s10096-023-04613-w.
Mahmoudi S, Pourakbari B, Sadeghi RH, Hamidieh AA, Safari Sharari A, Salajegheh P, et al. High prevalence of latent tuberculosis in hematopoietic stem cell transplant recipients: a first report. Pediatr Transpl. 2020;24:e13770. https://doi.org/10.1111/petr.13770.
Akı ŞZ, Sucak GT, Tunçcan ÖG, Köktürk N, Şenol E. The incidence of tuberculosis infection in hematopoietic stem cell transplantation recipients: a retrospective cohort study from a center in Turkey. Transpl Infect Dis. 2018;20:e12912. https://doi.org/10.1111/tid.12912.
Compagno M, Navarra A, Campogiani L, Coppola L, Rossi B, Iannetta M, et al. Latent tuberculosis infection in haematopoietic stem cell transplant recipients: a retrospective Italian cohort study in Tor Vergata University Hospital, Rome. Int J Environ Res Public Health. 2022;19:10693 https://doi.org/10.3390/ijerph191710693.
Lewalle P, Pochon C, Michallet M, Turlure P, Brissot E, Paillard C, et al. Prophylaxie des infections post-allogreffe: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer. 2019;106:S23–S34. https://doi.org/10.1016/j.bulcan.2018.08.017.
